Drug updated on 11/4/2024
Dosage Form | Implant (subcutaneous; 10.8 mg) |
Drug Class | Gonadotropin-releasing hormone agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate
- Indicated for use as palliative treatment of advanced carcinoma of the prostate.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Mammographic Breast Density (MBD) Reduction in Premenopausal Women: Goserelin achieved a 2.7% reduction in MBD among premenopausal women without a breast cancer history, with MBD returning to baseline post-treatment. Comparatively, tamoxifen and leuprolide acetate showed higher MBD reductions (13.4% and 8.9%, respectively), while nonhormonal interventions like vitamin D and isoflavones showed no reduction.
- Uterine Fibroids Treatment in Premenopausal Women: Goserelin was less effective in reducing abnormal uterine bleeding than oral progestogens (dienogest and desogestrel), with no significant effect on fibroid size observed.
- Safety in Prostate Cancer Treatment: Goserelin, compared to GnRH (gonadotropin-releasing hormone) antagonists (degarelix and relugolix), demonstrated a higher incidence of adverse cardiovascular events, with pooled risk ratios significantly favoring GnRH antagonists for lower cardiovascular events (0.57), cardiovascular death (0.49), and all-cause mortality (0.48).
- Uterine Fibroids: Goserelin was associated with vasomotor symptoms, such as hot flashes, in 55% of users, while oral progestogens (dienogest and desogestrel) did not show such adverse events.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Zoladex (goserelin) Prescribing Information. | 2023 | TerSera Therapeutics LLC, Deerfield, IL |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer | 2022 | European Heart Journal. Cardiovascular Pharmacotherapy |
Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials | 2021 | Jnci Cancer Spectrum |
Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy) | 2020 | The Cochrane Database of Systematic Reviews |